0001237899-20-000011.txt : 20200225
0001237899-20-000011.hdr.sgml : 20200225
20200225160326
ACCESSION NUMBER: 0001237899-20-000011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200224
FILED AS OF DATE: 20200225
DATE AS OF CHANGE: 20200225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BROWN MICHAEL S
CENTRAL INDEX KEY: 0001174475
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20650569
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-02-24
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001174475
BROWN MICHAEL S
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2020-02-24
4
M
0
2000
273.67
A
2643
D
Common Stock
2020-02-24
4
S
0
1956
419.0
D
687
D
Common Stock
2020-02-24
4
S
0
44
419.03
D
643
D
Common Stock
5000
I
by SLAT
Common Stock
11349
I
by Trust
Non-Qualified Stock Option (right to buy)
273.67
2020-02-24
4
M
0
2000
0.0
D
2024-01-02
Common Stock
2000
250
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
/s/**Michael S. Brown
2020-02-24